KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Prepaid Assets (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Prepaid Assets for 17 consecutive years, with $185.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets fell 7.81% year-over-year to $185.8 million, compared with a TTM value of $185.8 million through Dec 2025, down 7.81%, and an annual FY2025 reading of $185.8 million, down 7.81% over the prior year.
  • Prepaid Assets was $185.8 million for Q4 2025 at Biomarin Pharmaceutical, down from $204.3 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $224.8 million in Q3 2023 and bottomed at $104.5 million in Q4 2022.
  • Average Prepaid Assets over 5 years is $163.7 million, with a median of $169.3 million recorded in 2024.
  • The sharpest move saw Prepaid Assets soared 50.02% in 2023, then dropped 24.71% in 2024.
  • Year by year, Prepaid Assets stood at $110.4 million in 2021, then decreased by 5.36% to $104.5 million in 2022, then soared by 35.28% to $141.4 million in 2023, then soared by 42.54% to $201.5 million in 2024, then decreased by 7.81% to $185.8 million in 2025.
  • Business Quant data shows Prepaid Assets for BMRN at $185.8 million in Q4 2025, $204.3 million in Q3 2025, and $177.2 million in Q2 2025.